search tools

EBRD strengthens foundations of international trade and finance in Tunisia (EBRD - European Bank for Reconstruction and Development)

Edit Public Technologies 14 Apr 2016
(Source. EBRD - European Bank for Reconstruction and Development). traduction française. Bank organises two-day workshop on 14 and 15 April 2016 ... The workshop has been developed by IFS University College in partnership with the International Chamber of Commerce ... In 2014, Banque Tuniso-Koweïtienne (BTK) won EBRD awards for the Most Active Issuing Bank in Tunisia and for Deal of the Year in the southern and eastern Mediterranean region....

BeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer (BeiGene Ltd)

Edit Public Technologies 12 Apr 2016
He was previously Chief Medical Officer at Epizyme, and Vice President of Oncology Development and Interim Chief Medical Officer at Pharmacyclics, where he was involved in the development of ibrutinib, the BTK inhibitor currently approved for treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia....

News release: Asian gypsy moth eradication project slated for Portland (ODA - Oregon Department of Agriculture)

Edit Public Technologies 08 Apr 2016
kurstaki (Btk), a natural-occurring bacterium which has been used safely and effectively in other gypsy moth eradication projects throughout the US and in Oregon since 1984 ... The commercial Btk product being used in Portland is considered a low-risk pesticide product by US EPA and is certified as an organic product by the Organic Materials Review Institute (OMRI). Btk specifically affects moth larvae....

Did You Know These 11 Episodes Of ‘Criminal Minds’ Were Based On Real Life?

Edit Hollywood 08 Apr 2016
After 11 seasons, Criminal Minds has had a scary high number of murderers and serial killers ... 1. “The Thirteenth Step”. CBS. Season. 6, episode 13 ... 2. "The Big Wheel" ... 3 ... Denis Rader/BTK Killer ... The BTK Killer, later identified as Denis Rader, portrayed his crimes to the police ... Like the Keystone Killer, the BTK Killer had remained dormant for many years and when he began killing again, he contacted police about a crime they hadn’t caught yet ... ....

BeiGene Reports Fourth Quarter and Full Year 2015 Financial Results (BeiGene Ltd)

Edit Public Technologies 30 Mar 2016
(Source. BeiGene Ltd) ... Oyler, Chief Executive Officer of BeiGene ... Mr ... BGB-3111, a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK) Presented initial clinical data in patients with advanced B-cell malignancies in an oral presentation at the 2015 American Society of Hematology (ASH) annual meeting ... Jedd D ... BGB-3111 (BTK Inhibitor) Initiate combination study with BGB-A317 in the first half of 2016 ... GAAP)....

Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 (Sunesis Pharmaceuticals Inc)

Edit Public Technologies 23 Mar 2016
(Nasdaq.SNSS) today announced that the first subject has been dosed in a Phase 1A, randomized, double-blind, placebo-controlled dose-ranging study to investigate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of its oral, next-generation, non-covalently binding BTK-inhibitor, SNS-062, in healthy subjects ... SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK)....

Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent ...

Edit Stockhouse 23 Mar 2016
“As a non-covalently binding kinase inhibitor with preclinical activity against Cys-481S mutated B-cell malignancies, SNS-062 is an important new drug candidate with the potential to address the emerging resistance to currently marketed and clinical-stage covalent-binding BTK inhibitors,” said Daniel Swisher, Chief Executive Officer of Sunesis....

BeiGene Announces Presentations on BGB-283 and Other Pipeline Agents at the 2016 American Association for Cancer Research Annual Meeting (BeiGene Ltd)

Edit Public Technologies 16 Mar 2016
(Source. BeiGene Ltd). WALTHAM, Mass., March 16, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd ... In addition, BeiGene will present eight posters related to its pipeline agents including BGB-A317 (PD-1 antibody), BGB-3111 (BTK inhibitor), and BGB-283 during this AACR meeting ... Title ... Presenter. Dr ... Session ... et al.,CD40L-CD40 signaling on B-cell lymphoma response to BTK inhibitors ... et al.,BTK inhibitor BGB-3111 synergizes with lenalidomide in MCL models....

16 March 2016: STENTYS Reports 2015 Annual Results (Stentys SA)

Edit Public Technologies 16 Mar 2016
(Source. Stentys SA) 44253342-207d-4eaa-8d87-ec10f414feb4.pdf. STENTYS Reports 2015 Annual Results. Annual revenues up 58%. Gross margin up 1,671 bp ... PRINCETON, N.J ... Revenues ... 0 ... CE Marking for the STENTYS drug-eluting stent in treating BTK arteries. The STENTYS drug-eluting stent has received CE Marking for the treatment of BTK (Below-The-Knee) arteries, thus becoming the first self-expanding drug-eluting stent for this indication in Europe....

Azerbaijan allocates almost $590M for construction of BTK's Georgian part

Edit Topix 12 Mar 2016
The State Oil Fund of Azerbaijan allocated $588.2 million since the beginning of financing of the Baku-Tbilisi-Kars railway's construction, a message of SOFAZ said ... ....

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights (Sunesis Pharmaceuticals Inc)

Edit Public Technologies 10 Mar 2016
Soon, we expect to initiate clinical development of SNS-062, our differentiated non-covalent BTK inhibitor with a European Phase 1A clinical trial in healthy volunteers, followed by a Phase 1B/2 in B-cell malignancy patients later this year ... The presentations included preclinical data from the company's selective PDK1 inhibitors SNS-229 and SNS-510, as well as the company's potent noncovalent second-generation BTK inhibitor, SNS-062....

BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111 (BeiGene Ltd)

Edit Public Technologies 07 Mar 2016
We believe that BGB-3111 is the first BTK inhibitor being developed in China under the domestic regulatory pathway to enter the clinic ... BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-3111 has demonstrated greater selectivity against BTK than ibrutinib, the only BTK inhibitor currently approved by the U.S....

U.S. FDA Approves IMBRUVICA® (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia (Johnson & Johnson)

Edit Public Technologies 05 Mar 2016
(Source. Johnson & Johnson). HORSHAM, Pa., March 4, 2016 -The U.S ... and Pharmacyclics LLC, an AbbVie company ... 14.1, 22.0) ... IMBRUVICA works by blocking a specific protein called Bruton's tyrosine kinase (BTK). The BTK protein transmits important signals that tell B cells to mature and produce antibodies and is needed by specific cancer cells to multiply and spread. IMBRUVICA targets and blocks BTK, inhibiting cancer cell survival and spread ... ....
×
×
×
×